Terms & Conditions

Trending on PharmExec

Roundup: Novartis & Abogen Enter Licensing and Option Agreement, AstraZeneca and Daiichi Sankyo Enter Clinical Collaboration with Summit Therapeutics

Foghorn Therapeutics & Eli Lilly Halt Fhd-909 Development Following Phase I Data

How a Shift Towards Oral Medications Impacts GLP-1s

Pharmaceutical Executive Daily: Foghorn Therapeutics & Eli Lilly Discontinue Development of FHD-909

Regeneron and Sanofi Expand Antibody Alliance with Four New Drugs